EarningsQ2 2026 Earnings Report
TCHBF Q2 2026 EPS Results
Actual EPS$3.16
Consensus EPS$3.03
Beat/MissBeat by +$0.13
One Year Ago EPS$3.18
TCHBF Q2 2026 Revenue Results
Actual Revenue$515.54M
Expected Revenue$516.40M
Beat/MissMissed by -$862.20K
YoY Revenue Growth-2.72%
Earnings Announcement Details
QuarterQ2 2026
Date08/11/2026
TimeBefore Open
Conference CallTuesday, August 11, 2026
TCHBF Upcoming Earnings
Tecan Group AG's next earnings date is estimated for March 16, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
TCHBF Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call painted an overall constructive picture: Tecan delivered above-market sales growth in local currencies, maintained a healthy book-to-bill and recorded a resilient adjusted EBITDA margin with underlying profitability improvement. Management confirmed multi-year targets and reported early, tangible benefits from the Rewired transformation alongside strategic AI and geographic initiatives. However, material challenges remain — gross margin compression (material inflation, FX and tariffs), weaker operating cash flow, supply-chain shipment delays (Cavro), upfront transformation and IT costs, and weakness in the Academia & Government end market. On balance, the positive operational momentum, validated guidance and strategic progress outweigh the near-term financial and operational headwinds, but the company must execute Rewired and Elevate while stabilizing cash conversion and margins.Company Guidance
Above-Market Sales Growth
Group sales of CHF 427.5 million, up 3.4% in local currencies (reported -2.7% due to FX). Q2 sales growth sustained at +3.4% in local currencies.
Healthy Order Intake and Book-to-Bill
Order entry CHF 444.3 million, up 3.0% in local currencies. Book-to-bill ratio 1.04, above 1 in both Life Sciences and Partnering; Q2 orders stable year-on-year and exceeded Q1 levels.
Solid Adjusted EBITDA and Underlying Profitability
Adjusted EBITDA CHF 64.6 million with a margin of 15.1% (slightly ahead of the prior year). Adjusted EBITDA was only CHF 1.1 million below prior year and underlying profitability improved by c.108 basis points.
Broad-Based Segment Growth
Life Sciences sales +3.1% in local currencies (outperforming lab automation market); Partnering sales +3.6% in local currencies. Biopharma grew high single digits, Diagnostics mid-single digits, MedTech mid-single digits.
Regional and Product Drivers
Asia was the main growth driver with Japan very strong and China mid-single-digit growth; U.S. ~1% growth and Europe stable. Growth supported by liquid-handling instruments and Labwerx customized solutions.
Rewired Transformation Showing Early Benefits
Rewired launched as a 3-year program to drive >4% CAGR to 2028. H1 Rewired costs booked CHF 7.6 million; first savings are materializing and management expects meaningful contributions to 2027–2028 performance.
Strategic Operational Progress and Partnerships
Operational moves include closure of Boston design site, planned exits of selected Genomics activities, divestment of a precision machining site and consolidation in Vietnam, U.S. pipette-tip production operational. Strategic AI partnership with NVIDIA (Agentic AI for Introspect) and expansion into India.
Confirmed Guidance and 2028 Targets
Company reiterates full-year 2026 sales growth expectation of low single digits in local currencies and adjusted EBITDA margin guidance of 15.5%–16.5% (management expects to close toward the upper end). 2028 targets reaffirmed: CHF 1 billion sales and 20% adjusted EBITDA margin.
TCHBF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed